Ticker

Pernod Ricard (RI.PA) is rated a sell due to persistently weak operational results and an expensive valuation, even after recent share price declines. First-half net sales fell 14.9% reported and 5.9% organically, with flagship brands showing negative volume and pricing trends. Free cash flow growth was driven by lower capex and working capital shifts, not underlying business strength; per my calculations the…

Pernod Ricard SA (PRNDY) Q2 2026 Sales/Trading Call Transcript

Pernod Ricard said it is focused on cost-control after weakening sales and rising costs bit into the distiller's earnings.

Delivra Health Brands Inc. (TSX-V:DHB, OTCQB:DHBUF, FRA:3F0) said on Friday it has appointed John Barrett as a director, adding a former senior executive from major consumer goods companies as the health and wellness products maker looks to its next phase of growth. Barrett previously held senior roles at Frito-Lay and PepsiCo and served as chief commercial officer for Pernod Ricard USA.

Pernod Ricard (PDRDF/PRNDY) remains a sell as fundamentals deteriorate and no turnaround is in sight. Q1 FY26 sales were sharply negative in key markets—US down 16%, China down 27%—with volume declines persisting. Dividend sustainability is highly questionable; payout exceeds free cash flow for two years, with net debt at 8–9x FCF.